RasagilineBenefits, Dosage & Interactions

Rasagiline exerts its therapeutic effects by selectively and irreversibly inhibiting monoamine oxidase B (MAO-B). MAO-B is an enzyme found predominantly in the brain that is responsible for the breakdown of dopamine. By inhibiting MAO-B, rasagiline prevents the enzymatic degradation of dopamine in the brain, leading to increased and sustained levels of dopamine in the synaptic cleft. This action helps to alleviate the motor symptoms associated with Parkinson's disease, which are largely due to a deficiency of dopamine. Unlike some other MAO inhibitors, rasagiline is selective for MAO-B at recommended doses, meaning it has a lower propensity to inhibit MAO-A, an enzyme involved in the breakdown of other neurotransmitters like serotonin and norepinephrine. This selectivity helps to reduce the risk of certain side effects associated with non-selective MAO inhibitors, particularly the 'cheese effect' caused by tyramine interactions. (DrugBank, FDA label)

The primary benefit of rasagiline is its role in improving motor symptoms associated with Parkinson's disease. Clinical studies have demonstrated its efficacy in both early-stage and advanced Parkinson's disease. * **Monotherapy in Early Parkinson's Disease:** When used as a sole therapy in the early stages of Parkinson's disease, rasagiline has been shown to provide symptomatic relief, potentially delaying the need for levodopa therapy. It can help improve motor scores, reducing tremor, rigidity, and bradykinesia. (Cochrane Review, FDA label) * **Adjunctive Therapy in Advanced Parkinson's Disease:** In patients with more advanced Parkinson's disease who are already receiving levodopa, rasagiline can significantly reduce 'off' time (periods when levodopa is not working effectively and symptoms return). This leads to an increase in 'on' time without troublesome dyskinesia, improving overall motor function and quality of life. (FDA label, MedlinePlus) * **Neuroprotective Potential (Under Investigation):** Some research has explored the potential neuroprotective effects of rasagiline, suggesting it might slow the progression of Parkinson's disease by protecting dopaminergic neurons. However, definitive evidence for this neuroprotective effect in humans remains a subject of ongoing research and debate within the scientific community. Currently, rasagiline is approved based on its symptomatic benefits. (NIH ODS)

The efficacy of rasagiline in treating Parkinson's disease has been established through several randomized, placebo-controlled clinical trials. * **Early Parkinson's Disease (Monotherapy):** The TEMPO and ADAGIO studies provided key evidence for rasagiline's use as a monotherapy. The TEMPO study, a 26-week trial, showed that rasagiline significantly improved motor symptoms compared to placebo. The ADAGIO study explored both symptomatic and potential disease-modifying effects, demonstrating a significant symptomatic benefit. (FDA label, PubChem) * **Advanced Parkinson's Disease (Adjunctive Therapy):** The PRESTO and LARGO studies demonstrated the benefits of rasagiline as an add-on therapy for patients experiencing motor fluctuations while on levodopa. These trials showed that rasagiline significantly increased 'on' time and reduced 'off' time when added to a stable regimen of levodopa and other Parkinson's medications. (FDA label, Cochrane Review) Overall, the evidence supports rasagiline as an effective symptomatic treatment for Parkinson's disease, useful both as monotherapy in early stages and as an adjunct to levodopa in more advanced disease. The symptomatic benefits are consistently observed across various studies. (Cochrane Review)

Like all medications, rasagiline can cause side effects, although not everyone experiences them. The incidence and severity of side effects can vary. Common side effects, particularly when used as monotherapy, may include: * Headache * Flu-like syndrome * Joint pain (arthralgia) * Indigestion or dyspepsia When used as an adjunct to levodopa, some common side effects can be more pronounced due to increased dopamine activity: * Dyskinesia (involuntary movements, which may require adjustment of levodopa dose) * Orthostatic hypotension (a drop in blood pressure upon standing, leading to dizziness or lightheadedness) * Nausea and vomiting * Falls * Weight loss * Dry mouth * Insomnia or sleep disorders * Constipation Less common but more serious side effects can include: * Serotonin syndrome, especially when combined with certain antidepressants (see 'Do Not Mix') * Hallucinations or psychotic-like behavior * Impulse control disorders (e.g., pathological gambling, increased libido, compulsive shopping or eating) * Skin cancer (melanoma) – patients with Parkinson's disease may have an increased risk of melanoma, and it is unclear if this risk is increased or detected earlier with rasagiline use. Regular dermatological examinations are recommended. * Hypertensive crisis (a sudden, severe increase in blood pressure) if dietary restrictions for tyramine are not followed or if combined with certain medications. Patients should report any new or worsening symptoms to their healthcare provider. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Several warnings and precautions are associated with the use of rasagiline: * **Serotonin Syndrome:** There is a risk of developing serotonin syndrome when rasagiline is taken with other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and St. John's wort. Symptoms can include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination), and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Immediate medical attention is required if serotonin syndrome is suspected. * **Hypertensive Crisis:** Although rasagiline is selective for MAO-B, there is a potential for hypertensive crisis if dietary restrictions for tyramine are not followed or if it is combined with certain sympathomimetic agents. Tyramine is found in fermented, cured, or aged foods and beverages. While the risk with rasagiline at recommended doses is generally lower than with non-selective MAO inhibitors, caution is still advised. Patients should be informed about foods high in tyramine. * **Melanoma Risk:** Epidemiological studies have shown that patients with Parkinson's disease have a higher risk (2-6 times higher) of developing melanoma than the general population. It is unclear whether this increased risk is related to the disease itself or to the medications used to treat Parkinson's, including rasagiline. Patients should be monitored regularly for melanoma. * **Orthostatic Hypotension:** Rasagiline can cause orthostatic hypotension, especially when used in combination with levodopa. Patients should be advised to rise slowly from a sitting or lying position and to report any dizziness or lightheadedness. * **Hallucinations/Psychotic Behavior:** Hallucinations and psychotic-like behavior can occur, particularly in advanced Parkinson's disease patients or when used in combination with other dopaminergic medications. * **Impulse Control/Compulsive Behaviors:** Patients may experience urges to gamble, increased sexual urges, compulsive shopping, or other intense urges and inability to control these urges while taking dopaminergic medications, including rasagiline. If these behaviors develop, dose reduction or discontinuation should be considered. * **Dyskinesia:** Rasagiline can potentiate the effects of levodopa, and existing dyskinesia may become more pronounced or new dyskinesias may develop. A reduction in the levodopa dose may be necessary. * **Sleep/Somnolence:** Patients may experience somnolence, including falling asleep without warning (sleep attacks), especially when used in combination with other dopaminergic agents. Patients should be cautioned about operating machinery or driving. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Rasagiline is contraindicated in several situations due to the risk of serious adverse reactions: * **Concomitant use with other MAO Inhibitors:** Rasagiline should not be used with other monoamine oxidase (MAO) inhibitors, including other MAO-B inhibitors (e.g., selegiline), non-selective MAO inhibitors (e.g., phenelzine, tranylcypromine, isocarboxazid), or medications with MAO inhibitory activity (e.g., linezolid, methylene blue), due to the risk of hypertensive crisis or serotonin syndrome. A washout period of at least 14 days is required between discontinuing these drugs and starting rasagiline, and vice versa. * **Concomitant use with Meperidine:** The co-administration of rasagiline with meperidine is contraindicated due to the risk of serious adverse reactions, including serotonin syndrome and hyperpyrexia. * **Concomitant use with Tramadol, Methadone, Dextromethorphan, or St. John's Wort:** These substances can increase serotonin levels and lead to serotonin syndrome when combined with rasagiline. Therefore, their co-administration is contraindicated. * **Severe Hepatic Impairment:** Rasagiline is extensively metabolized by the liver. In patients with severe hepatic impairment, the exposure to rasagiline is significantly increased, raising the risk of adverse effects. Therefore, it is contraindicated in this population. * **Known Hypersensitivity:** Patients with a known hypersensitivity to rasagiline or any component of its formulation should not take this medication. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Rasagiline should not be mixed with several classes of medications and substances due to the potential for severe and life-threatening interactions, particularly serotonin syndrome or hypertensive crisis. **Do Not Mix With:** * **Other MAO Inhibitors:** All other monoamine oxidase (MAO) inhibitors, including selective MAO-A inhibitors, selective MAO-B inhibitors (e.g., selegiline), and non-selective MAO inhibitors (e.g., phenelzine, tranylcypromine, isocarboxazid). This also includes medications with MAO-inhibitory activity such as the antibiotic linezolid and the dye methylene blue. Combining these can lead to hypertensive crisis or serotonin syndrome. * **Meperidine:** A strong pain reliever. Co-administration can result in severe serotonin syndrome, hyperpyrexia, coma, and seizures. * **Other Serotonergic Drugs:** Including but not limited to: * Selective Serotonin Reuptake Inhibitors (SSRIs) like fluoxetine, paroxetine, sertraline, citalopram. * Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) like venlafaxine, duloxetine. * Tricyclic Antidepressants (TCAs) like amitriptyline, imipramine. * Tramadol (an opioid pain reliever). * Dextromethorphan (a cough suppressant). * Methadone (an opioid). * St. John's Wort (an herbal supplement). Combining these can lead to serotonin syndrome, a potentially fatal condition. * **Sympathomimetic Agents:** Including over-the-counter cold and allergy medications containing pseudoephedrine or phenylephrine, appetite suppressants, and stimulant medications (e.g., amphetamines, methylphenidate). These can lead to hypertensive crisis. * **Cyclobenzaprine:** A muscle relaxant, due to potential for serotonin syndrome. * **Tyramine-rich foods (in large quantities):** While rasagiline is selective for MAO-B, ingesting very large amounts of tyramine (found in aged cheeses, cured meats, fermented products, certain alcoholic beverages) may still carry a theoretical risk of hypertensive reaction. Patients should exercise caution with such foods and report any severe headache or other unusual symptoms immediately. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Rasagiline is typically taken once daily, in the morning. It can be taken with or without food. The dose is user-directed and must be set by a licensed clinician. Consistency in taking the medication at approximately the same time each day is generally recommended to maintain stable drug levels. If a dose is missed, it should not be doubled at the next scheduled time; patients should simply continue with their regular dosing schedule. (FDA label, MedlinePlus)